Rapid, inexpensive, and early detection of infectious viral diseases is an urgent unmet need with diverse applications ranging from clinical diagnosis, public health, and homeland security. Among these applications, Human Immunodeficiency Virus (HIV-1) diagnostics in resource-limited settings plays a critical role to provide appropriate and timely care to patients. More than 95% of deaths due to infectious diseases such as malaria, Acquired Immune Deficiency Syndrome (AIDS), and tuberculosis (TB) have been reported to occur in developing countries. A significant ratio (67%) of the 33.3 million HIV-1 infected population live in Sub-Saharan Africa. These statistics clearly highlight the urgent demand for rapid, inexpensive, and simple screening tests to identify infected individuals for HIV/AIDS treatment. However, current HIV-1 diagnostics such as lateral flow assays, including dipsticks or enzyme immunoassays (ELISA), and OraQuick HIV test kit lack the capability to detect acute HIV-1 infection even at high HIV-1 viral load. Detecting persons with acute HIV-1 infection is crucial since viral replication and shedding occur in this stage before detectable HIV-1 antibodies appear. Persons with acute HIV-1 infection are unaware of their disease and therefore contribute substantially to HIV-1 transmission. At this stage, there is maximum viral replication and shedding (108 copies/mL). Thus, there is an immediate need for easy to use, portable, and inexpensive diagnostic tool for acute HIV-1 detection (seroconversion and asymptomatic stages) at the POC. At the Bio-Acoustic MEMS in Medicine laboratory at Harvard Medical School, Dr. Demirci's (Sponsor) team has presented prototype viral load counting platforms based on lensless and fluorescence imaging. Here, I will employ my previous expertise in microfluidic cell electro-manipulation and my current expertise in antibody based HIV-1 virus capturing using micro/nano technologies to create a POC HIV-1 viral load measurement platform for treatment initiation and monitoring. Streptavidin-coated nano-magnetic beads conjugated with gp120 antibody will be used to selectively capture and isolate HIV-1 viruses from whole blood samples. The nanobead-HIV virus complexes will be then introduced into the microfluidic device with the optimized contactless microelectrodes functionalized with gp120 antibody to capture the nanobead-HIV complex. The captured viruses will be lysed through introducing a lysis detergent and the impedance change will be correlated to the viral load of the sample. This proposal will provide an inexpensive method for HIV-1 viral load measurements at POC that is compatible with mass fabrication technologies with a great promise to be commercialized.

Public Health Relevance

Rapid, inexpensive, and early detection of infectious viral diseases is an urgent unmet need with broad applications such as clinical diagnosis, public health, and homeland security. Of particular interest is the detection of HIV-1 at acute infection stage where current antibody based point-of-care (POC) technologies such as lateral flow assays, including dipsticks or enzyme immunoassays (ELISA), are not effective due to low concentration of antibodies. This project seeks to develop a novel microfluidic platform technology appropriate for HIV-1 viral load measurements to monitor anti-retroviral (ART) treatment in resource-limited settings. We will optimize and develop an easy to use, portable, disposable, and affordable platform to analyze tens of microliters of whole blood samples with a capability to be commercialized.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32AI102590-01A1
Application #
8527386
Study Section
Special Emphasis Panel (ZRG1-AARR-C (22))
Program Officer
Fitzgibbon, Joseph E
Project Start
2013-01-01
Project End
2015-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
1
Fiscal Year
2013
Total Cost
$53,942
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Safavieh, Mohammadali; Coarsey, Chad; Esiobu, Nwadiuto et al. (2017) Advances in Candida detection platforms for clinical and point-of-care applications. Crit Rev Biotechnol 37:441-458
Safavieh, Mohammadali; Khetani, Sultan; Juillard, Franceline et al. (2016) Electrical response of a B lymphoma cell line latently infected with Kaposi's sarcoma herpesvirus. Biosens Bioelectron 80:230-236
Asghar, Waseem; Yuksekkaya, Mehmet; Shafiee, Hadi et al. (2016) Engineering long shelf life multi-layer biologically active surfaces on microfluidic devices for point of care applications. Sci Rep 6:21163
Habibi, Neda; Kamaly, Nazila; Memic, Adnan et al. (2016) Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery. Nano Today 11:41-60
Safavieh, Mohammadali; Kanakasabapathy, Manoj K; Tarlan, Farhang et al. (2016) Emerging Loop-Mediated Isothermal Amplification-Based Microchip and Microdevice Technologies for Nucleic Acid Detection. ACS Biomater Sci Eng 2:278-294
Shafiee, Hadi; Kanakasabapathy, Manoj Kumar; Juillard, Franceline et al. (2015) Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. Sci Rep 5:9919
Tokel, Onur; Yildiz, Umit Hakan; Inci, Fatih et al. (2015) Portable microfluidic integrated plasmonic platform for pathogen detection. Sci Rep 5:9152
Asghar, Waseem; El Assal, Rami; Shafiee, Hadi et al. (2015) Engineering cancer microenvironments for in vitro 3-D tumor models. Mater Today (Kidlington) 18:539-553
Shafiee, Hadi; Asghar, Waseem; Inci, Fatih et al. (2015) Paper and flexible substrates as materials for biosensing platforms to detect multiple biotargets. Sci Rep 5:8719
Shafiee, Hadi; Wang, ShuQi; Inci, Fatih et al. (2015) Emerging technologies for point-of-care management of HIV infection. Annu Rev Med 66:387-405

Showing the most recent 10 out of 12 publications